DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Arixtra (Fondaparinux Sodium Subcutaneous) - Published Studies

 
 



Arixtra Related Published Studies

Well-designed clinical trials related to Arixtra (Fondaparinux Subcutaneous)

FONDAPARINUX FOR ISOLATED SUPERFICIAL-VEIN THROMBOSIS OF THE LEGS: A COST-EFFECTIVENESS ANALYSIS. [2011.07.14]

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. [2011.06.06]

Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. [2011.05.25]

Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. [2011.03]

Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience. [2011.01]

Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. [2010.12]

Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. [2010.12]

Fondaparinux for the treatment of superficial-vein thrombosis in the legs. [2010.09.23]

Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. [2010.02]

Fondaparinux in acute coronary syndromes. [2009.12]

Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. [2009.09]

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. [2009.07.28]

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. [2009.05]

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. [2009.03]

Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. [2009.03]

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. [2008.11.11]

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. [2008.02]

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. [2007.10.30]

Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. [2007.09.04]

Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. [2007.09]

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. [2007.06]

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. [2006.04.06]

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. [2006.04.05]

Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. [2006.03]

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. [2006.02.11]

Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. [2006.01]

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. [2005.12.01]

Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. [2005.10]

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. [2005.03.22]

Well-designed clinical trials possibly related to Arixtra (Fondaparinux Subcutaneous)

Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? [2011.02]

Anticoagulating obese patients in the modern era. [2011]

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. [2010.11]

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. [2010.08.12]

Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. [2010.01]

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. [2010]

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. [2009.03]

Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism. [2006.08.15]

Other research related to Arixtra (Fondaparinux Subcutaneous)

Fondaparinux - data on efficacy and safety in special situations. [2011.11.29]

Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. [2011.10]

[Comparison of platelet monitoring in patients receiving thromboprophylaxis with fondaparinux or a low molecular weight heparin. The Ariane study]. [2011.09]

Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. [2011.06]

Use of recombinant factor VIIa (NovoSeven((R))) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. [2011.06]

Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. [2011.05]

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. [2011.04]

Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. [2011.01]

Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. [2011]

Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. [2011]

Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. [2011]

Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience. [2011]

Low allergenic potential with fondaparinux: results of a prospective investigation. [2010.10]

Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. [2010.07.01]

Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia? [2010.06]

Update on fondaparinux: role in management of thromboembolic and acute coronary events. [2010.04]

Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. [2010.04]

Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. [2010.02]

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. [2010.02]

Low allergenic potential with fondaparinux: results of a prospective investigation. [2010]

Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. [2010]

Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. [2009.11.17]

Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. [2009.11]

Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. [2009.09]

Fondaparinux: an overview. [2009.06]

Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. [2009.05]

Heparin-induced thrombocytopenia successfully treated with fondaparinux. [2009.03]

Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. [2009.03]

[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report] [2008.12]

Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. [2008.12]

Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. [2008.11]

Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials. [2008.10.27]

Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. [2008.09]

Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. [2008.08]

Fondaparinux for the prevention or treatment of venous thromboembolism related to lower limb trauma: evidence today. [2008.04]

Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. [2008.04]

[Fondaparinux: the present and the future] [2008.03]

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. [2008.02]

Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. [2008.01]

Fondaparinux: use in thromboprophylaxis of acute medical patients. [2008]

Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. [2008]

Spotlight on fondaparinux sodium in acute coronary syndromes. [2008]

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. [2007.12.15]

The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. [2007.12]

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. [2007.12]

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. [2007.12]

Efficacy and safety of fondaparinux in patients with acute coronary syndromes. [2007.11]

Monitoring fondaparinux with the Sonoclot. [2007.10]

Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. [2007.09]

Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. [2007.08]

The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A MULTICENTRE, MULTINATIONAL, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP COMPARATIVE STUDY. [2007.07]

Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. [2007.06]

Fondaparinux as a treatment option for heparin-induced thrombocytopenia. [2007.06]

Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. [2007.04.28]

Fondaparinux: pharmacology and clinical experience in cardiovascular medicine. [2007.04]

Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. [2007.03]

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. [2007.01.16]

Management of acute coronary syndromes with fondaparinux. [2007]

Retroperitoneal hematoma due to spontaneous lumbar artery rupture during fondaparinux treatment. Case report and review of the literature. [2007]

Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. [2006.11]

Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. [2006.11]

Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. [2006.09.01]

Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. [2006.07]

Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. [2006.03]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014